Treatment of Moderate Hidradenitis Suppurativa

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 1, 2019

Study Completion Date

May 1, 2020

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Brodalumab

"Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8."

Trial Locations (1)

33134

Florida Academic Centers Research and Education, LLC, Coral Gables

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ortho Dermatologics

INDUSTRY

lead

Florida Academic Dermatology Centers

OTHER